Schroder Investment Management Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $426K | Sell |
8,806
-11,638
| -57% | -$500K | ﹤0.01% | 1103 |
|
|
2026
Q1 | $721K | Sell |
20,444
-3,604
| -15% | -$171K | ﹤0.01% | 1049 |
|
|
2025
Q4 | $1.23M | Buy |
24,048
+327
| +1% | +$16.7K | ﹤0.01% | 963 |
|
|
2025
Q3 | $1.32M | Buy |
23,721
+97
| +0.4% | +$5.68K | ﹤0.01% | 990 |
|
|
2025
Q2 | $1.63M | Buy |
23,624
+9
| +0% | +$612 | ﹤0.01% | 940 |
|
|
2025
Q1 | $1.64M | Buy |
23,615
+17,210
| +269% | +$1.42M | ﹤0.01% | 933 |
|
|
2024
Q4 | $549K | Sell |
6,405
-1,118
| -15% | -$121K | ﹤0.01% | 1091 |
|
|
2024
Q3 | $908K | Hold |
7,523
| – | – | ﹤0.01% | 1045 |
|
|
2024
Q2 | $1.07M | Buy |
7,523
+1,040
| +16% | +$138K | ﹤0.01% | 1019 |
|
|
2024
Q1 | $832K | Sell |
6,483
-2,023
| -24% | -$241K | ﹤0.01% | 1050 |
|
|
2023
Q4 | $880K | Sell |
8,506
-120
| -1% | -$11.9K | ﹤0.01% | 1028 |
|
|
2023
Q3 | $784K | Buy |
8,626
+70
| +0.8% | +$6.17K | ﹤0.01% | 1046 |
|
|
2023
Q2 | $692K | Buy |
8,556
+392
| +5% | +$32K | ﹤0.01% | 1088 |
|
|
2023
Q1 | $650K | Buy |
8,164
+12
| +0.1% | +$851 | ﹤0.01% | 1106 |
|
|
2022
Q4 | $552K | Buy |
8,152
+152
| +2% | +$8.91K | ﹤0.01% | 1129 |
|
|
2022
Q3 | $402K | Sell |
8,000
-1,104
| -12% | -$59.1K | ﹤0.01% | 1171 |
|
|
2022
Q2 | $508K | Hold |
9,104
| – | – | ﹤0.01% | 1170 |
|
|
2022
Q1 | $505K | Buy |
9,104
+1,104
| +14% | +$56.7K | ﹤0.01% | 1219 |
|
|
2021
Q4 | $448K | Buy |
+8,000
| New | +$433K | ﹤0.01% | 1131 |
|
|
2021
Q3 | – | Sell |
-160,000
| Closed | -$6.7M | – | 1541 |
|
|
2021
Q2 | $6.7M | Buy |
160,000
+152,000
| +1,900% | +$5.89M | 0.01% | 766 |
|
|
2021
Q1 | $270K | Hold |
8,000
| – | – | ﹤0.01% | 1297 |
|
|
2020
Q4 | $279K | Hold |
8,000
| – | – | ﹤0.01% | 1263 |
|
|
2020
Q3 | $275K | Hold |
8,000
| – | – | ﹤0.01% | 1154 |
|
|
2020
Q2 | $262K | Hold |
8,000
| – | – | ﹤0.01% | 1070 |
|
|
2020
Q1 | $243K | Hold |
8,000
| – | – | ﹤0.01% | 1075 |
|
|
2019
Q4 | $232K | Hold |
8,000
| – | – | ﹤0.01% | 1146 |
|
|
2019
Q3 | $207K | Sell |
8,000
-8,000
| -50% | -$202K | ﹤0.01% | 1146 |
|
|
2019
Q2 | $408K | Buy |
16,000
+8,000
| +100% | +$198K | ﹤0.01% | 1099 |
|
|
2019
Q1 | $209K | Buy |
+8,000
| New | +$197K | ﹤0.01% | 1068 |
|
|
2018
Q4 | – | Sell |
-8,000
| Closed | -$189K | – | 1270 |
|
|
2018
Q3 | $189K | Hold |
8,000
| – | – | ﹤0.01% | 1130 |
|
|
2018
Q2 | $182K | Buy |
+8,000
| New | +$190K | ﹤0.01% | 1163 |
|
|
2015
Q3 | – | Sell |
-5,160
| Closed | -$141K | – | 1213 |
|
|
2015
Q2 | $141K | Hold |
5,160
| – | – | ﹤0.01% | 1064 |
|
|
2015
Q1 | $139K | Hold |
5,160
| – | – | ﹤0.01% | 1094 |
|
|
2014
Q4 | $109K | Sell |
5,160
-8,240
| -61% | -$184K | ﹤0.01% | 1163 |
|
|
2014
Q3 | $319K | Buy |
+13,400
| New | +$308K | ﹤0.01% | 1136 |
|
Other funds holding NVO
F
Schroder Investment Management Group's NVO Position: Q2 2026 in Review
Schroder Investment Management Group reduced its Novo Nordisk (NVO) stake by 57% in Q2 2026, selling an estimated $500K and leaving 8,806 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #1103.
Schroder Investment Management Group first reported a position in NVO in Q3 2014 and has held it in 35 quarters since. The position peaked at $6.7M in Q2 2021. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Schroder Investment Management Group held 8,806 shares of Novo Nordisk worth $426K as of Q2 2026.
- Schroder Investment Management Group sold 11,638 Novo Nordisk shares in Q2 2026, an estimated $500K.
- Novo Nordisk made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #1103 holding.
- Schroder Investment Management Group first reported a position in Novo Nordisk in Q3 2014 and has held it in 35 quarters since.
- Schroder Investment Management Group's Novo Nordisk position peaked at $6.7M in Q2 2021.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.